Novo Nordisk has reported a rise in second-quarter revenues and hiked its full-year forecasts, but the positive results did not stop its share price falling sharply on some disappointing news for its shareholders. Second-quarter sales came in at DKK 78.5 billion ($12.1 billion), a rise of 3%, which was a little ahead of expectations. All told, sales of Wegovy pill were DKK 3.2 billion (just under $500 million) in the quarter, with five million prescriptions written to date, while the injectable product grew 1% to DKK 19.5 billion. Meanwhile, Novo Nordisk also said that CagriSema was unable to show non-inferiority to Lilly's injectable GIP/GLP-1 agonist Zepbound (tirzepatide) in the head-to-head REIMAGINE 4 trial in patients with type 2 diabetes, mirroring the outcome of a comparative study (REDEFINE 4) in obesity/overweight. While CagriSema matched Lilly's fast-growing drug on percentage change in body weight, it fell short on HbA1c, a marker of blood glucose control.